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A MARKOV MODEL FOR THE SPREAD OF HEPATITIS C
VIRUS
L. COUTIN, L. DECREUSEFOND, AND J.S. DHERSIN
Abstract. We propose a Markov model for the spread of Hepatitis C virus
(HCV) among drug users who use injections. We then proceed to an asymp-
totic analysis (large initial population) and show that the Markov process is
close to the solution of a non linear autonomous differential system. We prove
both a law of large numbers and functional central limit theorem to precise
the speed of convergence towards the limiting system. The deterministic sys-
tem itself converges, as time goes to infinity, to an equilibrium point. This
corroborates the empirical observations about the prevalence of HCV.
1. Motivations
Hepatitis C virus (HCV) infects 170 million people in the world (3 % of the
population) and 9 million in Europe (1 % of the population) [16]. More than 75 %
of newly infected patients progress to develop chronic infection. Then, Cirrhosis
develops in about 10 % to 20 %, and liver cancer develops in 1 % to 5 % over a
period of 20 to 30 years. These long-term consequences, which suggest an increased
mortality due to HCV infection, make the prevention of spread of hepatitis C a
major public health concern.
HCV is spread primarily by direct contact with human blood. In developed
countries that have safe blood supplies, the population infected by HCV is closely
related to injecting drug users (IDU). It is estimated that 90 % of infectious are due
to IDU [11]. In order to reduce the numbers of new hepatitis C cases, preventing
infections in IDU is then a priority. Programs exist all over the world which try to
reduce the prevalence of many infectious diseases like HIV or hepatitis C, among
injecting drug users. They are mainly based on needle exchanges. It turns out that
after several years of such programs, the HIV prevalence seems to be now rather
low whereas the percentage of IDU who are HCV positive remains about 60 %
[9, 11]. We were asked by epidemiologists to provide them a mathematical model
which could quantitatively evaluate the differences between the two diseases.
It is always a challenge to analyze an epidemic problem because there are so
many real-life situations that should be incorporated while keeping the mathemat-
ical model tractable. Moreover, epidemic field studies are expensive and hard to
organize so that parameter estimates are rare and often imprecise. It is thus nec-
essary to deal with parsimonious models whose parameters have clear and visible
meaning. To the best of our knowledge, the only models which have been developed
for the dynamics of HCV transmission are found in the references [14, 4]. It is a de-
terministic model with more than twenty-five parameters, for which the authors do
not have explicit results for the asymptotics and only estimate them by simulations.
In our paper, we propose a parsimonious Markovian model for the spread of HCV
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in a local population of IDU. It should be noted that our model bears some resem-
blance to a random SIR (Susceptible-Infected-Recovered) model but differs from it
by some essential characteristics. Our Susceptible (respectively Infected) are IDU
who are sero-negative (respectively sero-positive). There is no Recovered category
in our model since we can’t measure their number (when they are no longer IDU,
they can’t be counted in studies focused on drugs users). Moreover, our population
is not closed (there are new susceptible all the time) and a new drug user may be
infected at his first injection. This means that there is an exogeneous flow to the
Infected category, a feature which is not included in usual SIR models.
To keep the Markovian character of our model, we made the following usual
and reasonable hypothesis. Exogenous antibody-positive and antibody-negative
individuals arrive in this local population according to Poisson processes. If initiated
by an antibody-positive drug addict, a new IDU acquires the virus very rapidly after
the initiation [1, 6]. HCV then spreads in the population by sharing syringe, needles
and other accessories (cotton, boilers, etc.). Each individual of the population
stays in his state (infected/non infected) for an exponentially distributed time. We
present the model in Section 3. If we denote by X1(t) (resp. X2(t)) the number of
antibody-positive (resp. antibody-negative) individuals in the local population at
time t, we prove that the process X = (X1, X2) is an ergodic Markov process. In
Section 4., we give a related deterministic differential system connected with this
Markov process. We study its asymptotic behaviour and give an explicit expression
of the limit of the solution. In Section 5., we give a mean-field approximation of
the process X : For large populations, we prove that the process X is close to the
solution ψ of the deterministic differential system. In Section 6., we prove that,
for large populations, the invariant distribution for the Markov process X can be
approximated by the Dirac measure which only charges ψ(∞). Hence we can give
an explicit limit of the prevalence of HCV in the population. In Section 7, we
give a central limit theorem for the approximation of X by ψ when the population
tends to infinity. In Section 8, we show that even for a small value of N , there is a
good accordance between the prevalence computed on the deterministic limit and
the prevalence observed on the stochastic model. We also show that this can be
extended to the sensitivity of the model with respect to slight variations of some
parameters.
2. Preliminaries
Let us denote by D([0, T ],R2) the set of cadlag functions equipped with its usual
topology. In this Section, we recall some results about cadlag semi-martingales; for
details we refer to [10]. We assume that we are given (Ω, (Ft, t ≥ 0), P) a filtered
probability space satisfying the so-called usual hypothesis. On (Ω, (Ft, t ≥ 0), P),
let X and Y be two real-valued cadlag square integrable semi-martingales. The
mutual variation of X and Y , denoted by [X, Y ], is the right continuous process
with finite variation such that the following integration by parts formula is satisfied:
X(t)Y (t)−X(0)Y (0) =
∫
(0, t]
X(s−) dY (s) +
∫
(0, t]
Y (s−) dX(s) + [X, Y ]t.
The Meyer process of the couple (X, Y ), or its square bracket, is denoted by 〈X, Y 〉
is the unique right continuous with finite variation predictable process such that
X(t)Y (t)−X(0)Y (0)− 〈X, Y 〉t
is a martingale. Alternatively, 〈X, Y 〉 and is the unique right continuous, pre-
dictable with finite variation, process such that [X, Y ] − 〈X, Y 〉 is a martingale.
For a vector valued semi-martingaleX = (X1, X2) whereX1 and X2 are real valued
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martingales, we denote by 〈〈X 〉〉, its square bracket, defined by
〈〈X 〉〉t =
( 〈X1 〉t 〈X1, X2 〉t
〈X1, X2 〉t 〈X2 〉t
)
.
In the sequel, if x is a vector (resp. M a matrix) we denote by ‖x‖ (resp. ‖M‖) its
L
1-norm.
Let E be a discrete denumerable space. Let (X(t), t ≥ 0) be an E-valued, pure
jump Markov process, with infinitesimal generator Q = (qxy, (x, y) ∈ E × E). For
any F : E → R, Dynkin’s Lemma states that the process:
F (X(t))− F (X(0))−
∫ t
0
QF (Xs) ds
is a local martingale, where
QF (x) =
∑
y 6=x
(F (y)− F (x))qxy .
Here and hereafter, we identify the matrix Q and the operator Q defined as above.
3. Markov model
We consider the dynamics of HCV among a local population which suffers a con-
tinuous arrival of exogenous antibody-positive individuals, described by a Poisson
process of intensity r. We let X1(t) and X2(t) denote the number of antibody-
positive, respectively antibody-negative, users at time t in the population under
consideration. The new susceptible drug users arrive as a Poisson process of inten-
sity λ. We assume that for their first injection, they are initiated by an older IDU
who has a probability q(t) = X1(t)(X1(t)+X2(t))
−1 of being infected. For different
reasons, even in this situation, the probability of being infected, is not exactly one
and is denoted by pI . Each time, an antibody-negative IDU has an injection, he
may share some of his paraphernalia and may become infected if the sharing occurs
with an infected IDU. We summarize all these probabilities by saying that at each
injection, the probability of becoming infected is pq(t), where p is a parameter to
be estimated, as is pI . If we denote by α the rate at which an IDU injects, and if
αp is small, we can assume that the rate at which a sane IDU in the population is
infected, is given by αpq(t). Once infected, an IDU may exit from the population
under consideration either by a death, self healing or stopping drug usage. The
whole of these situations is modeled by an exponentially distributed duration with
parameter µ1. For antibody-negative IDU, the only way to exit the population is
by stopping drug injection, supposed to happen after an exponentially distributed
duration with parameter µ2. In summary, the transitions are described in Figure 1.
For further references, we set
q1(n1, n2) = r + λ pI
n1
n1 + n2
q2(n1, n2) = µ1 n1
q3(n1, n2) = αpn2
n1
n1 + n2
q4(n1, n2) = λ(1 − pI n1
n1 + n2
)
q5(n1, n2) = µ2 n2.
Lemma 3.1. Let x0 = (x01, x
0
2). Conditionally on X(0) = x
0, the process W (t) =
X1(t)+X2(t)− (x1+x2) is dominated (for the strong stochastic order of processes)
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VHC-
n2
VHC+
n1
α pn2
n1
n1 + n2
λ(1− pI
n1
n1 + n2
)
r + λ pI
n1
n1 + n2 µ1 n1
µ2 n2
Figure 1. Transitions of the Markov model.
by a Poisson process of intensity r + λ. In particular, for any t ∈ [0, T ],
E
[
sup
t≤T
‖X(t)‖p
∣∣∣X(0) = x0] ≤ (‖x0‖+ (r + λ)T )p,
for any p ≥ 1.
Proof. It suffices to say that by suppressing all the departures, we get another
system with a population larger than that of the system under consideration, at
any time, for any trajectory. Then, XN1 (t) + X
N
2 (t) − (x1 + x2) is less than the
number of arrivals of a Poisson process of intensity r + λ. Since a Poisson process
has increasing path, its supremum over [0, T ] is its value at time T . The second
assertion follows. 
Theorem 3.1. The Markov process X = (X1, X2) is ergodic. For r > 0, the
process X is irreducible. For r = 0, the set {(n1, n2) ∈ N×N, n1 = 0} is a proper
closed subset.
Proof. Let S be the function defined on N×N by
S(n1, n2) = ‖(n1, n2)‖ = n1 + n2.
If we denote by Q the infinitesimal generator of X , we have
QS(n1, n2) = λ+ r − µ1n1 − µ2n2.
LetK be a real strictly greater than (λ+r+1)/µ− where µ− = µ1∧µ2 and consider
the following finite subset of the state space:
DK = {(n1, n2) ∈ N×N, n1 + n2 ≤ K}.
If (n1, n2) belongs to D
c
K , then
QS(n1, n2) ≤ λ+ r − µ−(n1 + n2) < −1.
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Lemma 3.1 implies that both
E
[
sup
s∈[0, 1]
S(X(s))
]
and E
[∫ 1
0
|QS(X(s))| ds
]
are finite. Then according to [12, Proposition 8.14], X is ergodic.
The second and third assertions are immediate through inspection of the transi-
tion rates. 
With the non-linearity appearing in the transitions, it seems hopeless to find
an exact expression for the stationary probability of the Markov process (X1, X2).
As usual in queueing theory [12], we then resort to asymptotic analysis in order
to gain some insights on the evolution of this system. This means that we let the
initial population becoming larger and larger. For keeping other quantities of the
same order of magnitude, one are thus led to increase r and λ at the same speed,
i.e., keeping the ratio i = (r + λ)/(x1 + x2) constant. Note that in epidemiological
language, i is the incidence of new susceptible. It is measured in percentage of
individuals per unit of year.
4. A deterministic differential system
The mean field approximation will lead us to investigate the solutions of the fol-
lowing differential system with initial condition x0 = (x01, x
0
2) ∈ (R+×R+)\ {(0, 0)}:
(Sr(x
0))


ψ′1(t) = r + λ pI
ψ1(t)
ψ1(t) + ψ2(t)
− µ1 ψ1(t) + α p ψ1(t)ψ2(t)
ψ1(t) + ψ2(t)
,
ψ1(0) = x
0
1,
ψ′2(t) = λ(1 − pI
ψ1(t)
ψ1(t) + ψ2(t)
)− µ2 ψ2(t)− αp ψ1(t)ψ2(t)
ψ1(t) + ψ2(t)
,
ψ2(0) = x
0
2.
Theorem 4.1. For any x0 = (x01, x
0
2) ∈ (R+×R+)\ {(0, 0)}, there exists a unique
solution to (Sr(x
0)). Furthermore, this solution is defined on R. For r > 0, the
differential system has a unique fixed point (ξ1, ξ2) in R+ × R+, defined by the
equations
(1) ξ2 =
1
µ2
(r + λ− µ1ξ1) and ξ1 = ab− c+ sgn(a)
√
(ab− c)2 + 4abrµ1
2aµ1
,
where a = αp− µ1 + µ2, b = r+ λ and c = rµ1 + λ(1− pI)µ2. Moreover, for r > 0
and any x0 ∈ R2+\{0, 0},
lim
t→+∞
(ψ1(t), ψ2(t)) = (ξ1, ξ2).
If r = 0 and x01 = 0 then
ψ1(t) = 0 for all t and lim
t→+∞
(ψ1(t), ψ2(t)) = (0, λ/µ2).
If r = 0 and ρ = αp + µ2pI − µ1 > 0, then there exists two equilibrium points:
one is (0, λ/µ2) and the other is the unique solution with positive first coordinate
of (1). If x01 > 0 then
lim
t→+∞
(ψ1(t), ψ2(t)) = (ξ1, ξ2).
If r = 0 and ρ ≤ 0, then for any x0 with positive x01,
lim
t→+∞
(ψ1(t), ψ2(t)) = (0, λ/µ2).
For further references, we denote by ψ∞ the unique point to which the system
converges in each case. We denote by Ψ the measurable function such that Ψ(x0, t)
is the value of the solution of (Sr(x
0)) at time t.
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Proof. We denote by f1 and f2 the functions such that (Sr(x
0)) is written
(2) ψ′1(t) = f1(ψ1(t), ψ2(t)) and ψ
′
1(t) = f2(ψ1(t), ψ2(t)).
Since f1 and f2 are locally Lipschitz, there exists a local solution for any starting
point x0 belonging to (R+ ×R+)\ {(0, 0)}. Moreover, for any (x1, x2) ∈ (R+ ×
R+)\ {(0, 0)},
r − µ1x1 ≤ f1(x1, x2) ≤ r + λpI + αpx1 and λ(1− pI)− µ2x2 ≤ f2(x1, x2) ≤ λ.
By standard theorems about comparison of solutions of differential equations, one
can then show that every local solution ψ can be extended to R and that for any
t ∈ R, ψ(t) = (ψ1(t), ψ2(t)) belongs to (R+ ×R+)\ {(0, 0)}. Furthermore, with
direct calculations, we have
(3)
d
dt
(ψ1(t) + ψ2(t)) = r + λ− µ1ψ1(t)− µ2ψ2(t).
For ε > 0, consider
Aε± = {(x1, x2) ∈ R+ ×R+, 0 ≤ ±(r + λ− µ1x1 − µ2x2) < ε},
Bε+ = {(x1, x2) ∈ R+ ×R+, r + λ− µ1x1 − µ2x2 ≥ ε},
Bε− = {(x1, x2) ∈ R+ ×R+, r + λ− µ1x1 − µ2x2 ≤ −ε},
and
A0 = {(x1, x2) ∈ R+ ×R+, r + λ− µ1x1 − µ2x2 = 0}.
According to (3), on Bε+, the derivative of ψ1 + ψ2 = ‖(ψ1, ψ2)‖ is greater than
ε, hence for a starting point in Aε+, the trajectory has an L
1 increasing norm.
Reasoning along the same lines on Bε−, we see that for any η > 0, for any starting
point outside A0, the trajectory of the differential system enters, in a finite time,
one of the set Aη+ or A
η
−. Moreover, upon this time, the orbit stays in the compact
Aη+ ∪Aη− forever. It follows that (see for instance [13])
lim
t→+∞
dist
(
(ψ1(t), ψ2(t)), A
0
)
= 0.
This implies that any invariant set M must be included in A0. We then seek
for a maximal invariant set. It is given by the intersection of the sets Zi =
{(x1, x2), fi(x1, x2) = 0}, i = 1, 2. We then remark that this system of equation
is equivalent to the system f1 + f2 = 0 and f2 = 0. It turns out that
(f1 + f2)(x1, x2) = r + λ− µ1x1 − µ2x2 = 0.
The equation f2(x1, x2) = 0 yields to
x1 =
µ2x
2
2 − λx2
λ(1 − pI)− (αp+ µ2)x2 = h(x2).
The variations of h shows that h is a strictly decreasing diffeomorphism from I =
[λ(1− pI)/(αp+ µ2), λ/µ2] onto R+. Hence its reciprocal function is a decreasing
diffeomorphism from R+ onto I.
Assume first that r > 0. Then (λ+ r)/µ2 > λ/µ2 and there exists one and only
one equilibrium point whose coordinates (ξ1, ξ2) are thus given by the solution of
(1) – see Figure 2 for an illustration.
Consider the two distinct situations where µ1 = µ2 and µ1 6= µ2. If µ1 6= µ2, then
for any starting point (x1, x2) 6= (ξ1, ξ2) belonging to A0, ψ′1(x1, x2)+ψ′2(x1, x2) =
0 but µ1ψ
′
1(x1, x2)+µ2ψ
′
2(x1, x2) 6= 0. Hence for t sufficiently close to 0, ψ(t) does
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x1
x2
{f1 + f2 = 0} {f1 = 0}
{f2 = 0}
λ
µ
2
λ + r
µ2
λ + r
µ1
λ(1− pI)
αp + r
(ξ1, ξ2)
Figure 2. Determination of the fixed point.
not belong to A0 and then (x1, x2) does not belong to M . Thus, M = {(ξ1, ξ2)}
and according to the Poincaré-Bendixson theorem (see [13] for example),
(4) lim
t→+∞
(ψ1(t), ψ2(t)) = (ξ1, ξ2).
If µ1 = µ2 then ψ1 + ψ2 is solution of the differential equation
v′(t) = r + λ− µ1v(t), v(0) = x1 + x2.
By direct integration, this yields to
(ψ1 + ψ2)(t) = (x1 + x2)e
−µ1t +
r + λ
µ1
(1− e−µ1t).
This entails that A0 is invariant. Since A0 is compact, there exists a minimum
invariant set, say M . According to the Poincaré-Bendixson theorem, M is either a
periodic orbit or a critical point. Since ψ1 + ψ2 is not periodic, M is also reduced
to (ξ1, ξ2) and we have (4).
For r = 0, the point (0, λ/µ2) is a fixed point. Due to the concavity of h
−1,
the sets A0 and {f2 = 0} have at most one point of intersection with positive
abscissa. The existence of it depends on the slope of h−1 at the origin. By direct
computations, we find that
(h−1)′(0) = −(αp
µ2
+ pI).
Hence there exists another equilibrium point if and only if (h−1)′(0) > µ1/µ2, i.e.,
ρ = αp+ µ2pI − µ1 > 0. We still denote by (ξ1, ξ2) the unique solution of (1) with
a strictly positive first coordinate. Note first that if x1 = 0 then ψ1(t) = 0 for any t
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thus the vertical axis is an invariant set. Moreover, for x1 = 0, a direct integration
of (Sr(x
0)) shows that
lim
t→+∞
(ψ1(t), ψ2(t)) = (0, λ/µ2).
We hereafter assume that x1 6= 0. If αp + µ2pI − µ1 ≤ 0, the same reasoning as
above shows that
lim
t→+∞
(ψ1(t), ψ2(t)) = (0, λ, /µ2).
Assume now that αp + µ2pI − µ1 > 0. At (0, λ/µ2), the linearization of (Sr(x0))
gives a matrix whose determinant is given by
d = −ρµ2.
Then, according to the hypothesis, d < 0 thus (0, λ/µ2) is a saddle point and
cannot be an attractor. Reasoning as above again yields to the conclusion that
every orbit converges to (ξ1, ξ2) for any (x1, x2) such that x1 6= 0. 
5. Mean field approximation
We now consider a sequence (XN(t) = (XN1 (t), X
N
2 (t)), t ≥ 0) of Markov pro-
cesses with the same transitions as above but with different rates given by (with
self evident notations):
qN1 (n1, n2) = rN + λN pI
n1
n1 + n2
qN2 (n1, n2) = µ1 n1
qN3 (n1, n2) = αpn2
n1
n1 + n2
qN4 (n1, n2) = λN (1− pI
n1
n1 + n2
)
qN5 (n1, n2) = µ2 n2.
The main result of this Section is the following mean field approximation of the
system XN .
Theorem 5.1. Assume that
E
[∥∥∥∥ 1NXN (0)− x0
∥∥∥∥
2
]
N→+∞−−−−−→ 0, 1
N
rN
N→+∞−−−−−→ r ≥ 0, 1
N
λN
N→+∞−−−−−→ λ.
Let ψ(x0, .) = (ψ1(x
0, .), ψ2(x
0, .)) be the solution of the differential system (Sr(x
0)).
Then, for any T > 0,
E
[
sup
t≤T
∥∥∥∥ 1NXN(t)− ψ(x0, t)
∥∥∥∥
2
]
N→+∞−−−−−→ 0.
Before turning into the proof of Theorem 5.1, let us give the martingale problem
satisfied by the process XN .
Theorem 5.2. For any N > 0, the process XN is a vector-valued semi-martingale
with decomposition:
XN1 (t) =X
N
1 (0) +
∫ t
0
(qN1 + q
N
3 − qN2 )(XN(s)) ds+MN1 (t)
XN2 (t) = X
N
2 (0) +
∫ t
0
(qN4 − qN3 − qN5 )(XN (s)) ds+MN2 (t),
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where MN = (MN1 , M
N
2 ) is a local martingale vanishing at zero with square bracket
given by:
〈〈MN 〉〉t =


∫ t
0
(qN1 + q
N
3 + q
N
2 )(X
N (s)) ds −
∫ t
0
qN3 (X
N (s)) ds
−
∫ t
0
qN3 (X
N (s)) ds
∫ t
0
(qN4 + q
N
3 + q
N
5 )(X
N (s)) ds

 .
Proof. Using the martingale problem associated with the Markov process XN , we
get that, for t ≥ 0,
XN(t) = XN(0) +


∫ t
0
(qN1 + q
N
3 − qN2 )(XN (s)) ds∫ t
0
(qN4 − qN3 − qN5 )(XN (s)) ds

+MN(t),
where MN = (MN1 , M
N
2 ) is a 2-dimensional local martingale vanishing at zero.
Let us now compute its square bracket. First of all, we consider 〈MN1 ,MN2 〉. By
integration by parts, we get that, for t ≥ 0,
XN1 (t)X
N
2 (t) = X
N
1 (0)X
N
2 (0) +
∫
(0,t]
XN1 (s−) dX
N
2 (s)
+
∫
(0,t]
XN2 (s−) dX
N
1 (s) + [X
N
1 , X
N
2 ]t,
where [XN1 , X
N
2 ] denotes the mutual variation of X
N
1 and X
N
2 . Hence
XN1 (t)X
N
2 (t) = X
N
1 (0)X
N
2 (0) +
∫ t
0
XN1 (s)(q
N
4 − qN3 − qN5 )(XN (s)) ds
+
∫ t
0
XN2 (s)(q
N
1 + q
N
3 − qN2 )(XN (s)) ds
+ [XN1 , X
N
2 ]t
+ local martingale.
Now, writing the martingale problem associated with the process XN1 X
N
2 , we have
XN1 (t)X
N
2 (t) = X
N
1 (0)X
N
2 (0) +
∫ t
0
XN1 (s)(q
N
4 − qN5 )(XN (s)) ds
+
∫ t
0
XN2 (s)(q
N
1 − qN2 )(XN (s)) ds
+
∫ t
0
(XN2 (s)−XN1 (s)− 1)qN3 (XN(s)) ds
+ local martingale.
We conclude that
〈XN1 , XN2 〉t = −
∫ t
0
qN3 (XN (s)) ds.
Similar arguments show that
〈XN1 〉t =
∫ t
0
(qN1 +q
N
3 +q
N
2 )(X
N (s)) ds and 〈XN2 〉t =
∫ t
0
(qN4 +q
N
3 +q
N
5 )(X
N (s)) ds
which ends the proof. 
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Proof of Theorem 5.1. According to Theorem 4.1, for any x0 ∈ R+×R+ \ {(0, 0)}
infs∈R+ ‖ψ(x0, s)‖ > 0. Then, the theorem 5.1 is a consequence of the following
Lemma. 
Lemma 5.1. There exists a constant C depending only on r, λ, PI , µ1, µ2 and αp
such that for any x0 ∈ R+ ×R+ \ {(0, 0)}, any (XM (0))M∈N sequence of random
variables taking its values in R×R \ {(0, 0)}, for any N ∈ N∗, and for any T > 0
E
[
sup
t≤T
∥∥∥∥ 1NXN(t)− ψ(x0, t)
∥∥∥∥
∣∣∣∣ σ(XM (0), M ∈ N)
]
≤
(∥∥∥∥ 1NXN(0)− x0
∥∥∥∥
2
+
1
N
(
T + T 2
1
N
‖XN(0)‖
))
× exp
(
T
∫ T
0
(1 +
1
‖ψ(x0, s)‖)
2ds
)
.
Proof of Lemma 5.1. Let us fix T > 0. Using Theorem 5.2, we have
1
N
XN1 (t) =
1
N
XN1 (0) +
∫ t
0
1
N
(qN1 + q
N
3 − qN2 )(XN (s)) ds+
1
N
MN1 (t),
1
N
XN2 (t) =
1
N
XN2 (0) +
∫ t
0
1
N
(qN4 − qN3 − qN5 )(XN (s)) ds+
1
N
MN2 (t).
Moreover,
ψ1(t) =
∫ t
0
(q1 + q3 − q2) (ψ(s)) ds,
ψ2(t) =
∫ t
0
(q4 − q3 − q5) (ψ(s)) ds.
Note that for x = (x1, x2) and y = (y1, y2) in R+ ×R+ \ {(0, 0)}, then∣∣∣∣ x1x1 + x2 −
y1
y1 + y2
∣∣∣∣ ≤
∣∣∣∣x1 − y1y1 + y2
∣∣∣∣+
∣∣∣∣ x1x1 + x2 −
x1
y1 + y2
∣∣∣∣
=
∣∣∣∣x1 − y1y1 + y2
∣∣∣∣+
∣∣∣∣ x1x1 + x2
y1 − x1 + y2 − x2
y1 + y2
∣∣∣∣
≤ 2‖x− y‖‖y‖ .
We also have ∣∣∣∣ x1x2x1 + x2 −
y1y2
y1 + y2
∣∣∣∣ ≤ 2‖x− y‖.
From now on, we use C for positive constants which depend only on r, λ, pI , µ1,
µ2 and αp, and which may vary from line to line. For 0 ≤ t ≤ T ,
∥∥∥∥ 1NXN (t)− ψ(x0, t)
∥∥∥∥
2
≤C
(∥∥∥∥ 1NXN (0)− ψ(x0, 0)
∥∥∥∥
2
+ T 2
∣∣∣r − rN
N
∣∣∣2 + T 2
∣∣∣∣λ− λNN
∣∣∣∣
2
(5)
+ T
∫ t
0
(
1 +
1
‖ψ(x0, s)‖
)2 ∥∥∥∥ 1NXN (s)− ψ(x0, s)
∥∥∥∥
2
ds+
1
N2
∥∥MN (t)∥∥2
)
.
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Using Burkholder-Davis-Gundy inequality, we get that
E[ sup
t∈[0,T ]
∥∥MN(t)∥∥2 |σ(XM (0), M ∈ N)] ≤ CE[∣∣〈〈MN 〉〉T ∣∣ |σ(XM (0), M ∈ N)].
As a consequence of Lemma 3.1 we get that for i ∈ {1, 2, 3, 4, 5},
(6) E
[
sup
t≤T
qNi (Xs)
]
≤ C(‖XN (0)‖+ (rN + λN )T ),
and
E[
∣∣〈〈MN 〉〉T ∣∣ |σ(XM (0), M ∈ N)] ≤ CT (E [‖XN(0)‖]+ (rN + λN )T ).
Hence, using Gronwall’s lemma, (5) implies that
E
[
sup
t≤T
∥∥∥∥ 1NXN(t)− ψ(x0, t)
∥∥∥∥
∣∣∣∣ σ(XM (0), M ∈ N)
]
≤
(∥∥∥∥ 1NXN(0)− x0
∥∥∥∥
2
+
1
N
(
T + T 2
1
N
‖XN(0)‖
))
× exp
(
T
∫ T
0
(1 +
1
‖ψ(x0, s)‖)
2ds
)
.

6. Stationary regime
We have proved so far that the process N−1XN converges, as N goes to infinity,
to a deterministic R2-valued function. This function converges, as t goes to infinity,
to a fixed point ψ∞. On the other hand, for each N , the Markov process XN is
ergodic thus has a limiting distribution as t goes to infinity. This raises the natural
question to know whether this limiting distribution converges to the Dirac mass at
ψ∞ when N goes to infinity. Let us denote by PY N , ν the distribution of the process
Y N = N−1XN under initial distribution ν. We denote by Pψ, ν the distribution
of the process whose initial state is chosen according to ν and whose deterministic
evolution is then given by the differential system (Sr(x
0)). According to Theorem
3.1, we know that XN has a stationary probability whose value is irrespective of
the initial distribution of XN . We denote by Y N(∞) a random variable whose
distribution is the stationary measure of Y N . We already know that
PY N (t),δ
x0
N→∞−−−−→ Pψ(t), δ
x0
t→∞
y yt→∞
PY N (∞)
?−−−−→
N→∞
δψ∞
The question is then to prove that this is a commutative diagram, i.e., that Y N (∞)
converges in distribution to the Dirac measure at the equilibrium point of the
system (Sr(x
0)). We borrow the proof from [15] and [7] but we need to take into
consideration the special role of the point (0, 0) which is a singular point for some
of the qj .
Definition 1. We say that a probability measure ν on R+ ×R+ \ {(0, 0)} belongs
to P0 when ν({0, 0}) = 0.
We will show that 1) for any sequence of initial distribution νN converging
weakly to ν with ν ∈ P0 then PY N , νN converges weakly to Pψ, ν , 2) that for
any probability measure ν ∈ P0, Pψ(t), ν converges weakly to δψ∞ , 3) that the
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sequence (Y N (∞), N ≥ 1) is tight and 4) that any possible accumulation point of
(Y N (∞), N ≥ 1) belongs to P0.
The proof is then short and elegant: since (Y N (∞), n ≥ 1) is tight, it is sufficient
to prove that there is a unique possible limit to any convergent sub-sequence of
(Y N (∞)). We still denote by Y N (∞) such a converging sub-sequence (as N goes
to infinity). Its limit is denoted by ν, known to belong to P0. According to Point
1. above, PY N ,P
Y N (∞)
converges weakly to Pψ, ν . Moreover by the properties of
Markov processes, PY N ,P
Y N (∞)
is the distribution of a stationary process, hence ψ
is also a stationary process when started from ν. This means that the distribution
of ψ(t) is ν for any t. Then, by Point 2. above, ν = δψ∞ . We have thus proved
that any convergent sub-sequence of Y N (∞) converges to δψ∞ , hence the result.
We now turn to the proof of the three necessary lemmas.
Theorem 6.1. For any sequence of initial distribution νN converging weakly to
ν ∈ P0, then PY N , νN converges weakly to Pψ, ν .
Proof. We will proceed in two steps: First prove the tightness in D([0, T ], R2) and
then identify the limit. Actually, we will prove the slightly stronger result that
PY N , νN is tight and that the limiting process is continuous. According to [2], we
need to show that for each positive ǫ and η, there exists δ > 0 and n0 such that for
any N ≥ n0,
P

 sup
|v−u|≤δ
v,u≤T
‖Y N (v)− Y N (u)‖ ≥ ǫ

 ≤ η.
We denote by
AN1 (t) =
1
N
∫ t
0
(qN1 + q
N
3 − qN2 )(XN (s)) ds
AN2 (t) =
1
N
∫ t
0
(qN4 − qN3 − qN5 )(XN (s)) ds.
From Theorem 5.2, we know that
Y Ni (v) = A
N
i (v) +
1
N
MNi (v), i = 1, 2.
Hence, for any positive a,
(7) P

 sup
|v−u|≤δ
v,u≤T
‖Y N (v)− Y N (u)‖ ≥ ǫ

 ≤ P(‖Y N (0)‖ ≥ a)
+P( sup
|v−u|≤δ
v,u≤T
‖AN (v)−AN (u)‖ ≥ ǫ/2; ‖Y N (0)‖ ≤ a)
+P( sup
|v−u|≤δ
v,u≤T
1
N
‖MN(v)−MN(u)‖ ≥ ǫ/2; ‖Y N (0)‖ ≤ a).
Eqn. (6) implies that
E
[
sup
s≤T
1
N2
‖MN(s)‖2
∣∣∣∣ ‖Y N (0)‖ ≤ a
]
≤ C(a+ 1)
N
.
This means that (N−1MN , N ≥ 1) converges to 0 in L2(Ω;D([0, T ],R2), P.|‖Y N (0)‖≤a).
Hence it converges in distribution in D([0, T ],R2) and thus it is tight. This means
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that the last summand of (7) can be made as small as needed for large N . Further-
more,
‖AN (v)−AN (u)‖ ≤ 2
N
∫ v
u
5∑
i=1
qi(X
N(s))ds
≤ 2|v − u|
(
rN + λN
N
+
C
N
sup
s≤T
‖XN(s)‖
)
.
It follows from Lemma 3.1 that
E

 sup
|v−u|≤δ,
v,u≤T
‖AN (v)−AN (u)‖
∣∣∣∣ ‖Y N (0)‖ ≤ a

 ≤ Cδ (rN + λN
N
T + a)
≤ C((r + λ)T + a)δ.
This means that the second summand of (7) can also be made as small as wanted.
The hypothesis on the initial condition exactly means that this also holds for the
first summand of (7). Thus we have proved so far that PY N , νN is tight and that
its limit belongs to the space of continuous functions.
We now prove that the only possible limit is Pψ, ν . Assume that ν
N tends to
ν and that PY N , νN tends to some PZ, ν . We suppose that the initial conditions
XN(0) of the Markov processes are distributed as νN and we introduce a random
variable x0 distributed as ν. Recall that Y N = N−1XN . We fix M ∈ N∗, (αk =
(αk1 , α
k
2))0≤k≤M ∈ R2M+2 and 0 = t0 ≤ t1 ≤ ... ≤ tM . We introduce
GN = E
(
exp i
[
M∑
k=0
< αk, Y
N (tk) >
])
,
G˜N = E
(
exp i
[
M∑
k=0
< αk, ψ(
XN(0)
N
, tk) >
])
,
G = E
(
exp i
[
M∑
k=0
< αk, ψ(x
0, tk) >
])
,
where Y N (−1) = 0, and Y N = N−1XN , with initial condition XN (0) distributed
as νN and X
0 as ν.
Let ε > 0. The sequence (νN )N∈N is tight, hence there exits a compact set
K ⊂ R+ ×R+ \ {(0, 0)} such that ν(Kc) + supN νN (Kc) ≤ ε. We also introduce
GNK = E
(
exp i
[
M∑
k=0
< αk, Y
N (tk) >
]
1K(
XN(0)
N
)
)
,
G˜NK = E
(
exp i
[
M∑
k=0
< αk, ψ(
XN (0)
N
, tk) >
]
1K(
XN (0)
N
)
)
,
GK = E
(
exp i
[
M∑
k=0
< αk, ψ(x
0, tk) >
]
1K(x
0)
)
.
Then,
lim sup
N
∣∣G−GN ∣∣ ≤ 2ε+ lim sup
N
|G˜NK −GNK |+ lim sup
N
|G˜NK −GNK |.
From Theorem 4.1, the map (x, s) 7→ ψ(x, s) is continuous on (R+ × R+ \
{(0, 0)}) × [0, T ] and inf(x,s)∈K×[0,T ] ‖ψ(x, s)‖ > 0. Since X
N
N (0) takes is value in
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the compact set K, then from Lemma 5.1, lim supN |G˜NK − GNK | = 0. Since the
sequence of measures (νN ) converges weakly to ν, then lim supN |G˜NK − GNK | = 0.
Hence,
lim sup
N
∣∣G−GN ∣∣ ≤ 2ε
for all ε > 0.
That means for any t0, · · · , tM ,
P(Y N (t0),··· ,Y N (tM )),νN
N→0−−−→ P(ψ(x0,t0),··· ,ψ(x0,tN )),ν ,
Hence all the accumulation points are the same and the convergence of PY N ,νN
follows. 
Theorem 6.2. For any probability measure ν ∈ P0, Pψ(t), ν converges weakly to
δψ∞ as t→∞.
Proof. For any f continuous bounded on R2, we have
∫
fdPψ(t), ν =
∫
R2
E [f(ψ(t)) |ψ(0) = x] dν(x).
Theorem 4.1 says that for any x ∈ R+ ×R+ \ {(0, 0)},
E [f(ψ(t)) |ψ(0) = x] t→∞−−−→ f(ψ∞).
The result follows by dominated convergence. 
Theorem 6.3. The sequence (Y N (∞), N ≥ 1) is tight and any accumulation point
belongs to P0.
We need a preliminary lemma which relies on the observation that when µ1 =
µ2, the process X1 + X2 has the dynamics of the process counting the number
of customers in an M/M/∞ queue. Recall that µ− = min(µ1, µ2) and set ζ =
(r + λpI)/µ−. For any c ∈ R+, any x ∈ N, define the function
hc(t, x) = (1 + ce
µ−t)xe−ζc exp(µ−t).
Note that hc is increasing with respect to x. Moreover, according to [12, Chapter
6],
(8)
∂hc
∂t
(t, x) +R(hc(t, .))(x) = 0,
where, for any w : N→ R,
Rw(x) = (w(x + 1)− w(x))(r + λpI) + (w(x − 1)− w(x))µ−x.
Lemma 6.1. For any non negative real c, the process Hc = (hc(t,X1(t)+X2(t)), t ≥
0) is a positive supermartingale.
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Proof. According to Dynkin formula (see [12, Proposition C.5]), for any 0 ≤ s < t,
we have
0 = E
[
hc(t, ‖X(t)‖)− hc(s, ‖X(s)‖)−
∫ t
s
∂hc
∂t
(r, ‖X(r)‖)
− (r + λpI)
∫ t
s
(
hc(r, ‖X(r)‖ + 1)− hc(r, ‖X(r)‖)
)
dr
−
∫ t
s
(
hc(r, ‖X(r)‖ − 1)− hc(r, ‖X(r)‖)
)
(µ1X1(r) + µ2X2(r)) dr
∣∣∣∣Fs
]
≥E
[
hc(t, ‖X(t)‖)− hc(s, ‖X(s)‖)−
∫ t
s
∂hc
∂t
(r, ‖X(r)‖)
− (r + λpI)
∫ t
s
(
hc(r, ‖X(r)‖ + 1)− hc(r, ‖X(r)‖)
)
dr
−
∫ t
s
(
hc(r, ‖X(r)‖ − 1)− hc(r, ‖X(r)‖)
)
µ−(X1(r) +X2(r)) dr
∣∣∣∣Fs
]
,
where the inequality follows from the monotony of hc and the definition of µ−.
Hence we get that
0 ≥ E
[
hc(t, ‖X(t)‖)− hc(s, ‖X(s)‖)
−
∫ t
s
∂hc
∂t
(r, ‖X(r)‖) +R(hc(r, .))(‖X(r)‖) dr
∣∣∣∣Fs
]
.
In view of Eqn. (8), we get
0 ≥ E [hc(t, ‖X(t)‖)− hc(s, ‖X(s)‖) | Fs] ,
i.e., Hc is a supermartingale.
Now, let (Y N (∞), N ≥ 1) be a subsequence which converge to ν. Since XN(∞)
is a random variable distributed according to the stationary law of the process XN ,
E
[
Qe−‖.‖(XN(∞))
]
= 0.
By a direct calculation, we have
Qe−‖.‖(x) = e−‖x‖[(λ + r)(e−1 − 1) + (µ1x1 + µ2x2)(e− 1)],
then
(λN + rN )(1− e−1)E
[
e−N‖Y
N (∞)‖
]
= N(e− 1)E
[
e−N‖Y
N (∞)‖(µ1Y
N
1 (∞) + µ2XN2 (∞))
]
.
Hence, (1− e−1)(r + λ)ν({(0, 0)}) = 0, i.e., ν belongs to P0. 
Proof of Theorem 6.3. Let K be real, for any positive real θ, we have
P(‖Y N (t)‖ > K) = P(‖XN(t)‖ > NK) ≤ e−θNKE [exp(θ‖XN (t)‖)] .
Lemma 6.1 entails that
E
[
exp(θ‖XN(t)‖)] ≤ (1 + (eθ − 1)e−µ−t)N‖XN (0)‖ exp(Nζ(eθ − 1)(1− e−µ−t)).
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Hence,
P(‖Y N (∞)‖ > K) = lim
t→∞
P(‖Y N (t)‖ > K)
≤ inf
θ>0
lim
t→∞
(
1 + (eθ − 1)e−µ−t)N‖XN (0)‖ exp(−θNK +Nζ(eθ − 1)(1 − e−µ−t))
= inf
θ>0
exp
(
N(−θK + ζ(eθ − 1))
≤ exp(−1
2
NK lnK),
for K large enough. The tightness follows. 
7. Central Limit Theorem
It turns out that we can also evaluate the order of the approximation when we
replace XN by ψ. This is given by CLT like theorem.
Theorem 7.1. Assume that the hypothesis of Theorem 5.1 holds. Then, for any
T > 0, the process
WN =
√
N(Y N − ψ)
tends in distribution in D([0, T ], R2) to a centered Gaussian process with covariance
matrix Γ(t) given by:
Γ(t) =


Γ1(t) −αp
∫ t
0
ψ1(s)ψ2(s)
ψ1(s) + ψ2(s)
ds
−αp
∫ t
0
ψ1(s)ψ2(s)
ψ1(s) + ψ2(s)
ds Γ2(t)

 ,
where
Γ1(t) = rt+
∫ t
0
λ pI
ψ1(s)
ψ1(s) + ψ2(s)
+ µ1 ψ1(s) + αp
ψ1(s)ψ2(s)
ψ1(s) + ψ2(s)
ds
Γ2(t) =
∫ t
0
λ(1− pI ψ1(s)
ψ1(s) + ψ2(s)
) + µ2 ψ2(s) + α p
ψ1(s)ψ2(s)
ψ1(s) + ψ2(s)
ds.
Proof. According to [5, p. 339], it suffices to prove that
E
[
sup
t≤T
|WN (t)−WN (t−)|
]
N→+∞−−−−−→ 0
and that
〈〈WN 〉〉t N→+∞−−−−−→ Γ(t).
Since the jumps of Y N are bounded by 1/N , those of WN are bounded by N−1/2,
hence the first point is proved. As to the second point, remark that
〈〈WN 〉〉t = N−1〈〈MN 〉〉t
and then use Theorem 5.1. 
8. Numerical investigation
Another approach to evaluate the order of approximation can be made by com-
puter simulation. We simulated the Markov process for N = 100 and compute the
estimate of the prevalence by a simple Monte-Carlo method on 10, 000 trajectories.
For the parameters we chose, α = 1, µ1 = 0.1, µ2 = 0.2, r = 1, λ = 5 and pI = 0.8,
the results are strikingly good as shown in Figure 3. Note that the choice of pa-
rameters is here very delicate since biological parameters are not very well known
(i.e., µ1, µ2, p, . . .) and population dependant quantities are even more obscure to
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Figure 3. Prevalence with respect to p. The solid line represents
the value as computed by Equations 1. The dots represents the
simulated values. The 95% confidence interval are so small, they
can’t be displayed.
determine. We here chose parameters which seems reasonable and fit the observed
prevalence.
In such models, another quantity of interest is the relative importance of each
parameters: what does affect most the prevalence ? On the deterministic system,
this question is easily solved by computing the derivative of the prevalence with
respect to each of the parameters. We now explain how to compute the sensitivity
of the prevalence on the stochastic model. Say we have a function F bounded which
depends on the sample-paths of X , we aim to compute:
d
dp
Ep[F ],
where we put a p under the expectation symbol to emphasize the dependence of
the underlying probability with respect to p. Other “greeks”, as these quantities
are called in mathematical finance, can be derived analogously. We assume that
we observe the Markov process on a time window of size T , i.e., any functional is
implicitly assumed to belong to FT = σ{X(s), 0 ≤ s ≤ T }.
Theorem 8.1. For any bounded F , F ∈ FT , we have:
d
dp
Ep[F ] =
1
p
Ep

F

∑
s≤T
1{(1,−1)}(∆X(s))−
∫ T
0
q3(X(s−)) ds




=
1
p
covp

F, ∑
s≤T
1{(1,−1)}(∆X(s))

 ,
where ∆X(s) = X(s)−X(s−).
Proof. The proof relies on the Girsanov theorem which is more easily expressed
in the framework of multivariate point measures. Since there are only five kind of
jumps, we can represent the dynamics ofX as a point measures onR+×{1, · · · , 5}:
µ([0, t]× {i}) =
∑
s≤t
1{∆X(s)=li},
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where
l1 = (1, 0), l2 = (−1, 0), l3 = (1, −1), l4 = (0, 1) and l5 = (0, −1).
In the reverse direction,
X(t) = X(0) +
5∑
i=1
µ([0, t]× {i}) li.
It is immediate from the preceding results that νp, the Pp-predictable compensator
of µ is given by
dνp(t, i) = qi(X(t−)) dt.
To compute d/dpEp[F ] means to compute
lim
ε→0
1
ǫ
(Ep+ε[F ]−Ep[F ]) .
Under Pp+ε,
dνp+ε(t, i) = dνp(t, i) for i 6= 3 and dνp+ε(t, 3) = (1 + ε
p
) dνp(t, 3).
Let
U(t, i) =


0 if i 6= 3,
ε
p
if i = 3.
According to the Girsanov theorem (see [3, 8]), this means that
Ep+ε[F ] = Ep
[
F E(
∫ t
0
U(s, i)( dµ(s, i)− dνp(s, i)))
]
= Ep
[
F E
(
ε
p
(µ([0, T ]× {3})− νp([0, T ]× {3}))
)
,
]
where E denotes the Doléans-Dade exponential. It is known (see [3]) that a Doléans-
Dade exponential follows the same rule of derivation as a usual exponential, hence
the result. 
With the parameters above, the simulated greek coincides pretty well with the
sensitivity computed by differentiating the expression of the stationary prevalence
in the deterministic system, see Figure 4. However, as usual with this method, the
confidence interval are rather large.
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Figure 4. Prevalence greek with respect to p. Same conventions
as above. The error bars represent the 95% confidence interval.
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